scispace - formally typeset
J

Jeffrey Settleman

Researcher at Genentech

Publications -  190
Citations -  40059

Jeffrey Settleman is an academic researcher from Genentech. The author has contributed to research in topics: GTPase & Cancer. The author has an hindex of 78, co-authored 189 publications receiving 37539 citations. Previous affiliations of Jeffrey Settleman include Yale University & Harvard University.

Papers
More filters
Journal ArticleDOI

Epidermal growth factor receptor mutations in lung cancer

TL;DR: 'oncogenic shock' is described as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors, essential to the successful use of targeted therapies in common epithelial cancers.
Journal ArticleDOI

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

TL;DR: This review will provide potential mechanistic explanations for the association between EMT induction and the emergence of CSCs, and highlight recent studies implicating the function of TGF-β-regulated noncoding RNAs in driving EMT and promoting CSC self-renewal.
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes

Daniel J. Klionsky, +235 more
- 16 Feb 2008 - 
TL;DR: A set of guidelines for the selection and interpretation of the methods that can be used by investigators who are attempting to examine macroautophagy and related processes, as well as by reviewers who need to provide realistic and reasonable critiques of papers that investigate these processes are presented.
Journal ArticleDOI

Systematic identification of genomic markers of drug sensitivity in cancer cells

TL;DR: It was found that mutated cancer genes were associated with cellular response to most currently available cancer drugs, and systematic pharmacogenomic profiling in cancer cell lines provides a powerful biomarker discovery platform to guide rational cancer therapeutic strategies.